A Phase 1/2 interventional study of JBI-802 in Essential Thrombocythemia (ET) and Polycythemia Vera, sponsored by Jubilant Therapeutics Inc.. Recruiting at 7 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Jubilant Therapeutics Inc. · Phase 1/2, Interventional, and Treatment
…and 21 more changes, on the record history on ClinicalTrials.gov ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Thrombocythemia, Essential with a site in Australia — 7 open to participants now, 10 under way, 4 of them phase 3. Thrombocythemia, Essential · Australia.
Among the 18 studies in Thrombocythemia, Essential with a site in Australia, this one is the 14th largest by planned enrollment, is one of 3 that started in 2024, is one of 3 in phase 1/2, and was the 14th registered.
229 studies on the registry are indexed under Thrombocythemia, Essential; 37 are open to participants now.
Browse Thrombocythemia, Essential studies →7 of the 18 studies in Thrombocythemia, Essential with a site in Australia are open now. Recruiting first, the newest first:
Incyte Corporation · Sites in Australia, United States, Austria and 19 more countries
Ages 18+
Damora Therapeutics · Sites in Australia, United States
Ages 18+
Incyte Corporation · Sites in Australia, United States, Belgium and 8 more countries
Ages 18+
Eilean Therapeutics AU Pty Ltd · Sites in Australia
Ages 18–55 · Healthy volunteers
Incyte Corporation · Sites in Australia, United States, Belgium and 2 more countries
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 33 Thrombocythemia, Essential studies recruiting now, 29 (88%) set no upper age limit and 3 (9%) stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 7 · Phase 3 6
First in 2008; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is above the median of 53 across 168 interventional studies indexed under Thrombocythemia, Essential.
Median enrollment 140 across the 18 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 18 have an industry lead sponsor. The 10 most frequent:
Jubilant Therapeutics Inc. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Jubilant Therapeutics Inc. has 1 study filed under Thrombocythemia, Essential — fewer than ten, so there is no comparison to draw.
3 of the studies in Thrombocythemia, Essential with a site in Australia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06079879Phase 3Merck Sharp & Dohme LLCA Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) | 2027-07-14 |
| NCT06456346Phase 3Merck Sharp & Dohme LLCBomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) | 2027-09-28 |
| NCT07527221Eilean Therapeutics AU Pty LtdSafety and Tolerability of ZE74-0282 in Healthy Volunteers | 2026-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 18 studies in Thrombocythemia, Essential with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 1/2 study is evaluating the safety and preliminary effectiveness of JBI-802, an oral investigational medicine, in adults with essential thrombocythemia (ET) or polycythemia vera (PV) with thrombocytosis (high platelet counts).
The study has two parts. Part 1 evaluates different doses to select the recommended Phase 2 dose. The initial dose-escalation portion is complete, and additional participants may receive selected doses to further assess safety and activity. Part 2 will evaluate the selected dose in a larger group of participants with ET or PV.
JBI-802 is taken by mouth once daily in 28-day treatment cycles. Participants may continue treatment while they are benefiting, tolerating treatment, and meeting study requirements. Study assessments include medical examinations, laboratory tests, electrocardiograms, symptom assessments, bone marrow evaluations, and imaging when needed.
This is a multicenter, open-label Phase 1/2 study of oral JBI-802 in adults with ET or PV and thrombocytosis.
Part 1: Dose evaluation. The completed dose-escalation portion assessed increasing doses of JBI-802. Additional participants may receive selected doses to further evaluate safety, drug levels, biological effects, and preliminary clinical activity. The Safety Review Committee and Sponsor will use the available data to select the recommended Phase 2 dose.
Part 2: Dose expansion. After the recommended dose is selected, additional participants with ET or PV and thrombocytosis will receive that dose to further evaluate safety and clinical activity.
The study plans to enroll approximately 70 participants. Treatment may continue for up to 2 years, with a possible 12-month extension for participants who continue to benefit and meet protocol requirements.
The criteria were revised on the registry on Nov 17, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
JBI-802 - CoREST inhibitor (Dual LSD1 and HDAC6 inhibitor)
Drug: JBI-802
Drug: JBI-802
CoREST inhibitor dual targeting LSD1 and HDAC6
Dose Escalation - Incidence of Dose-Limiting Toxicities (DLTs)
Part 1: Number of participants with dose-limiting toxicity (DLT) events during the first 28-day treatment cycle Units: Number of participants
Time frame: At the end of Cycle 1 (each cycle is 28 days)
Dose Expansion - Platelet count
Part 2: Proportion of participants achieving a platelet count of 450 × 10⁹/L or lower.
Time frame: Up to 2 years
Dose Escalation - Incidence of Treatment-Emergent Adverse Events (TEAEs)
Incidence and severity of treatment-emergent adverse events and clinically significant changes in laboratory tests, vital signs, electrocardiograms, and physical examinations.
Time frame: From first dose up to 2 years
Pharmacokinetic measures
Pharmacokinetic measures of JBI-802 and its metabolites, including maximum concentration, time to maximum concentration, and area under the concentration-time curve. Units: ng/mL
Time frame: From Cycle 1 Day 1 up to Cycle 7 Day 1 (each cycle is 28 days)
Measures of clinical activity
3\. Measures of clinical activity, including platelet control, white blood cell normalization, hematocrit control in participants with ET/PV, and duration of platelet control.
Time frame: From first dose up to 2 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Jan 2031, 75 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Jun 2028 → Jan 2031 and completion Sep 2028 → Jan 2031.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
…and 21 more changes, on the record history on ClinicalTrials.gov ↗
…and 21 more changes, on the record history on ClinicalTrials.gov ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: JBI-802
Jubilant Therapeutics Inc.